United therapeutics corporation
UTHR 投資分析
看多重點:
- 價值≥4
- 股利≥2
分析結論
價值面獲得最高評分,但股利評分未超過2分,若公司開始配息,可能會有更優異的投資結果
UTHR 近期報酬表現
1.08%
United therapeutics corporation
0.98%
同產業平均
0.02%
S&P500
與 UTHR 同產業的標的表現
股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
---|---|---|---|---|---|---|---|
MNKD | Mannkind corporation | 2 分 | 3 分 | 2 分 | 2 分 | 1 分 | |
GYRE | Gyre therapeutics inc | 3 分 | 3 分 | 2 分 | 1 分 | 1 分 | |
MIRA | Mira pharmaceuticals inc | - | 2 分 | 2 分 | 1 分 | 1 分 | |
BMRN | Biomarin pharmaceutical inc | 3 分 | 3 分 | 2 分 | 3 分 | 1 分 | |
GILD | Gilead sciences, inc. | 4 分 | 1 分 | 1 分 | 3 分 | 4 分 |
- MNKD Mannkind corporation價值 2 分趨勢 3 分波段 2 分籌碼 2 分股利 1 分查看更多
UTHR 公司資訊
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind's Afrezza (insulin human) Inhalation Powder.